ImmunityBio Faces Securities Fraud Class Action Following FDA Warning and Significant Stock Drop

Overview of the Situation

ImmunityBio, Inc. (NasdaqGS IBRX) is currently at the center of a significant legal controversy involving a securities fraud class action. This arises after the company faced a warning from the U.S. Food and Drug Administration (FDA), which has led to a notable 21% drop in the company's stock price. The situation has garnered the attention of investors who suffered substantial losses during this troubling period. Kahn Swick & Foti, LLC, a well-respected law firm specializing in securities litigation, has reminded these investors of their potential legal rights and options available to them.

Class Action Details

The class action lawsuit is applicable to investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026. The deadline for filing lead plaintiff applications is set for May 26, 2026. The suit is currently pending in the United States District Court for the Central District of California, where many similar cases are processed due to their complexity and potential impacts on numerous investors.

Background of the FDA Warning

The crux of the issue stems from a warning letter issued by the FDA on March 13, 2026. The letter was made public on March 24, revealing that ImmunityBio's promotional materials misled consumers regarding the capabilities of Anktiva, a treatment for a specific type of bladder cancer. The FDA emphasized that the advertisements could create a false impression of Anktiva's effectiveness, misleading patients to believe that it could cure or prevent all forms of cancer. Following this revelation, ImmunityBio’s stock plummeted by $1.98 per share, closing at $7.42 per share on the day of the announcement.

Investor Rights and Legal Actions

For investors who believe they were misled or who suffered financial losses due to ImmunityBio's actions, Kahn Swick & Foti, LLC is advising them to explore their legal rights. The law firm is encouraging individuals to contact them for a consultation, highlighting that this initial discussion comes with no obligation or cost. Investors interested in participating in the legal process or serving as lead plaintiffs in this class action should act quickly to ensure their rights are protected under federal securities laws.

Who is Kahn Swick & Foti?

Kahn Swick & Foti, LLC, well-known in the securities litigation field, is led by its managing partner, Lewis Kahn, along with Charles C. Foti, Jr., a former Attorney General of Louisiana. The firm has a proven track record in helping investors recover losses caused by corporate fraud and malfeasance. KSF is recognized among the top 10 plaintiff law firms nationwide based on total settlement values, reinforcing their credibility and expertise in handling complex securities litigation. The firm's reach includes offices in key locations such as New York, California, and Louisiana, making them well-positioned to support investors across the country.

Conclusion

As ImmunityBio battles this challenge, the unfolding events highlight the broader issues of transparency and accountability in the pharmaceutical industry. Investors who feel they have been misled or suffered losses due to the company's actions are urged to take action before the application deadline on May 26, 2026. The legal protections in place aim to ensure that corporate actors are held accountable for their actions, safeguarding the interests of investors.

To learn more about the current situation or to explore potential legal avenues, investors can reach out to Kahn Swick & Foti, LLC for assistance.